Press & Media Coverage
Catch up on our latest press coverage
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
Imagion Biosystems to Present at Biotech Showcase 2024
MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that the
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems
[VIDEO] EGM Recording – 13 November 2023
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Quarterly Activity Report – Quarter ending 30 September 2023
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
[VIDEO] ShareCafe Hidden Gems Webinar Oct 2023
Imagion’s CEO, Isaac Bright, presents our latest investor opportunities at ShareCafe’s Hidden Gems Webinar on 20 October 2023. https://youtu.be/XCfQ64VeVCg Video Transcript: First up, we have
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.